204 related articles for article (PubMed ID: 28673185)
1. A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center.
Mohyuddin GR; Faisal MS; Badar T; Shah N; Bashir Q; Patel KK; Hosing C; Popat UR; Rondon G; Delgado R; Shah JJ; Weber DM; Thomas SK; Manasanch EE; Orlowski RZ; Champlin RE; Qazilbash MH
Leuk Lymphoma; 2018 Feb; 59(2):515-518. PubMed ID: 28673185
[No Abstract] [Full Text] [Related]
2. Autologous Hematopoietic Cell Transplantation for Dialysis-Dependent Myeloma: More Efficient, Less Toxic.
Amit O; Ram R
Acta Haematol; 2018; 139(2):104-105. PubMed ID: 29414800
[No Abstract] [Full Text] [Related]
3. Long-term follow-up of tandem autologous stem-cell transplantation in multiple myeloma.
Regelink JC; van Roessel CH; van Galen KP; Ossenkoppele GJ; Huijgens PC; Zweegman S
J Clin Oncol; 2010 Dec; 28(35):e741-3; author reply e744-5. PubMed ID: 21060027
[No Abstract] [Full Text] [Related]
4. Favorable prognostic impact of RAS mutation status in multiple myeloma treated with high-dose melphalan and autologous stem cell support in the era of novel agents: a single center perspective.
Gebauer N; Biersack H; Czerwinska AC; Schemme J; Hardel TT; Bernard V; Rades D; Lehnert H; Luley KB; Thorns C
Leuk Lymphoma; 2016; 57(1):226-9. PubMed ID: 25947035
[No Abstract] [Full Text] [Related]
5. Minimal residual disease evaluation in autologous stem cell transplantation recipients with multiple myeloma.
Gupta R; Kumar L; Dahiya M; Mathur N; Harish P; Sharma A; Sharma OD; Shekhar V
Leuk Lymphoma; 2017 May; 58(5):1234-1237. PubMed ID: 27658735
[No Abstract] [Full Text] [Related]
6. Autologous stem cell transfusions on multiple days in patients with multiple myeloma-Does it matter?
Moser S; Bacher U; Jeker B; Mansouri Taleghani B; Betticher D; Ruefer A; Egger T; Novak U; Pabst T
Hematol Oncol; 2019 Dec; 37(5):649-651. PubMed ID: 31483507
[No Abstract] [Full Text] [Related]
7. Tandem autologous versus autologous/allogeneic transplantation for multiple myeloma: propensity score analysis.
Kawamura K; Ikeda T; Hagiwara S; Mori T; Shinagawa A; Nishiwaki K; Ohashi K; Kubonishi S; Fukuda T; Ito T; Tomita N; Ichinohe T; Kato K; Morishima Y; Atsuta Y; Sunami K; Kanda Y
Leuk Lymphoma; 2016 Sep; 57(9):2077-83. PubMed ID: 26961137
[TBL] [Abstract][Full Text] [Related]
8. Submyeloablative total body irradiation-based conditioning and allogeneic stem cell transplantation in high-risk myeloma with early progression after up-front autologous transplantation.
Mai EK; Schmitt T; Radujkovic A; König L; Goldschmidt H; Ho AD; Luft T; Müller-Tidow C; Dreger P; Hegenbart U; Schönland SO
Br J Haematol; 2022 Jan; 196(1):244-248. PubMed ID: 34431093
[No Abstract] [Full Text] [Related]
9. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up.
Björkstrand B; Iacobelli S; Hegenbart U; Gruber A; Greinix H; Volin L; Narni F; Musto P; Beksac M; Bosi A; Milone G; Corradini P; Goldschmidt H; de Witte T; Morris C; Niederwieser D; Gahrton G
J Clin Oncol; 2011 Aug; 29(22):3016-22. PubMed ID: 21730266
[TBL] [Abstract][Full Text] [Related]
10. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Rodriguez TE; Hari P; Stiff PJ; Smith SE; Sterrenberg D; Vesole DH
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1391-1396. PubMed ID: 27164062
[TBL] [Abstract][Full Text] [Related]
11. The stepchild in myeloma treatments: is allogeneic transplantation not so bad after all?
Müller AMS; Kumar SK; Bruno B
Haematologica; 2019 Feb; 104(2):222-225. PubMed ID: 30705115
[No Abstract] [Full Text] [Related]
12. Tandem bone marrow transplantation in multiple myeloma.
Murashige N; Kishi Y
N Engl J Med; 2004 Apr; 350(14):1466-7; author reply 1466-7. PubMed ID: 15070801
[No Abstract] [Full Text] [Related]
13. Biosimilars of filgrastim in autologous stem cell transplantation: certain differences for myeloma patients only.
Nicol C; Henry C; Couturier MA; Delépine P; Tripogney C; Buors C; Guillerm G; Berthou C; Tempescul A; Ianotto JC
Leuk Lymphoma; 2017 Sep; 58(9):1-3. PubMed ID: 28278727
[No Abstract] [Full Text] [Related]
14. Prolonged survival with increasing duration of lenalidomide maintenance after autologous transplant for multiple myeloma.
Amsler IG; Jeker B; Mansouri Taleghani B; Bacher U; Betticher D; Egger T; Zander T; Luethi JM; Novak U; Pabst T
Leuk Lymphoma; 2019 Feb; 60(2):511-514. PubMed ID: 30616438
[No Abstract] [Full Text] [Related]
15. Syngeneic transplantation in multiple myeloma - a case-matched comparison with autologous and allogeneic transplantation. European Group for Blood and Marrow Transplantation.
Gahrton G; Svensson H; Björkstrand B; Apperley J; Carlson K; Cavo M; Ferrant A; Fouillard L; Gratecos N; Gratwohl A; Guilhot F; Lambertenghi Deliliers G; Ljungman P; Masszi T; Milligan DW; Powles RL; Reiffers J; Samson JD; Stoppa AM; Vernant JP; Volin L; Wallvik J
Bone Marrow Transplant; 1999 Oct; 24(7):741-5. PubMed ID: 10516677
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of patients with multiple myeloma treated with total body irradiation-Melphalan conditioning.
Munker R; Baghian A; Koleva Y; Andrews P; Matharoo GS; Wright AE; Saba NS; Weiner RS; Safah H
Eur J Haematol; 2017 Jul; 99(1):56-59. PubMed ID: 28370630
[TBL] [Abstract][Full Text] [Related]
17. Dose-intensified bendamustine and melphalan (BenMel) conditioning before second autologous transplantation in myeloma patients.
Farag S; Jeker B; Bacher U; Mansouri Taleghani B; Mueller BU; Novak U; Pabst T
Hematol Oncol; 2018 Oct; 36(4):671-678. PubMed ID: 30110717
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic Hematopoietic Cell Transplantation for Myeloma: When and in Whom Does It Work.
Bashir Q; Qazilbash MH
Curr Hematol Malig Rep; 2017 Apr; 12(2):126-135. PubMed ID: 28285435
[TBL] [Abstract][Full Text] [Related]
19. Tandem bone marrow transplantation in multiple myeloma.
Chng WJ
N Engl J Med; 2004 Apr; 350(14):1466-7; author reply 1466-7. PubMed ID: 15074003
[No Abstract] [Full Text] [Related]
20. Allografting or autografting for myeloma.
Moreau P; Harousseau JL; Attal M
N Engl J Med; 2007 Jun; 356(25):2646-8; author reply 2646-8. PubMed ID: 17600892
[No Abstract] [Full Text] [Related]
[Next] [New Search]
